Key Takeaways
- Leqselvi offers a promising new treatment for severe alopecia areata.
- Applied Clinical Trials showed strong, fast-acting results for Leqselvi.
- Patient support and accessibility are a priority for Sun Pharma.
News
Article
Sun Pharmaceutical Industries Announces U.S. Release of Severe Alopecia Areata Treatment Leqselvi
Author(s):
Leqselvi are currently available 8 mg tablets for severe Alopecia Areata treatments in adult patients.
Treatment options for severe alopecia areata in the US are limited.
Stock.adobe.com
Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently available to health care providers and adults suffering from severe alopecia areata.
Leqselvi (deuruxolitinib) is an 8 mg tablet oral selective inhibitor of Janus kinases JAK1 and JAK2 that is approved for the treatment of adults with severe alopecia areata.1
Why is the launch of Leqselvi So Important?
The launch of Leqselvi was crucial in the U.S. as treatment options for severe alopecia areata are limited, highlighting the importance of Leqselvi’s arrival.
When asked about the importance, Richard Ascroft, CEO of Sun Pharma North America, said, "The launch of Leqselvi in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them. As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community."1
During clinical trials, Leqselvi displayed rapid results with one third of patients noting the return of most of their hair 24 weeks into testing. This wasn’t the only positive out of the trial stage, as an additional 3% of patients reported upwards of 80% scalp coverage in just 8 weeks.
“The clinical evidence for Leqselvi is truly compelling, demonstrating consistent efficacy," said Arash Mostaghimi, MD, MPA, MPH, FAAD, Vice Chair of Clinical Trials and Innovation and Associate Professor of Dermatology at Brigham and Women's Hospital. Arash continued to say, “Leqselvi provides clinicians with an important new treatment that can deliver significant, rapid outcomes for patients with alopecia areata."1
There are more symptoms to alopecia areata than just hair loss. Adults suffering from severe alopecia areata can also reportedly suffer from psychosocial distress. This results in patients feeling a loss of self-confidence due to unexpected hair loss. As a result of this psychosocial symptom, a recent study revealed that 83% of patients suffering from severe alopecia areata prefer treatments that focus on time sensitivity, and desire rapid hair growth within treatments. Sun Pharma is aware of the demand for a fast-acting alopecia areata treatment and is committed to making Leqselvi readily available across the U.S.
To achieve this goal, Sun Pharma made Leqselvi accessible to patients through the Leqselvi Support Program. This program offers patients the ability to receive medications for a price as low as $0 for their first two years in the program.
Included in this program is a patient access liaison, a dedicated guide for patients who require assistance throughout their process.
"The availability of Leqselvi offers hope to our community, delivering a new, effective treatment option for adults living with severe alopecia areata," said Nicole Friedland, President and CEO, National Alopecia Areata Foundation (NAAF). "NAAF is thrilled to see expanded choices and increased opportunities for individuals to find an FDA-approved treatment to address hair loss caused by this autoimmune disease."1
What are the Side Effects of Leqselvi?
The reported side effects of patients taking Leqselvi may include:
- Serious infections
- Thrombosis
- Gastrointestinal perforations
- Malignancies
- Laboratory abnormalities
- Increased risk of major cardiovascular events and mortality
Additionally, it is advised that patients with poor CYP2C9 metabolizers or who are taking moderate to strong CYP2C9 inhibitors, should avoid using Leqselvi.
Sources
- Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata Sun Pharmaceutical Industries Ltd July 14, 2025 https://www.prnewswire.com/news-releases/sun-pharma-announces-launch-of-leqselvi-deuruxolitinib-in-the-united-states-for-the-treatment-of-severe-alopecia-areata-302504221.html
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Videos
Related Content
